We rank companies based on fund manager, research analyst and news sentiment
AIM stock icon

AIM ImmunoTech Inc.


About: AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

Employees: 28

Funds holding %
of 6,474 funds
Analysts bullish %
News positive %
of 10 articles

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

60% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 5

0.42% less ownership

Funds ownership: 8.89% [Q3] → 8.47% (-0.42%) [Q4]

3% less funds holding

Funds holding: 38 [Q3] → 37 (-1) [Q4]

7% less capital invested

Capital invested by funds: $1.97M [Q3] → $1.82M (-$147K) [Q4]

20% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 5

Research analyst outlook

We haven’t received any recent analyst ratings for AIM.

Financial journalist opinion

Based on 10 articles about AIM published over the past 30 days